P1076 / Impact of Oral Alendronate Therapy on BMD in HIV-Infected Children/Adolescents

P1076 is randomized, placebo-controlled, double blind pilot study of oral alendronate therapy in HIV-infected participants ≥ 11 to < 25 years of age not on antiretroviral treatment or on stable antiretroviral treatment and with low bone mineral density.  The study is designed to estimate and compare changes from pre-treatment levels in BMD of the lumbar spine and to assess the safety of alendronate.